Arcellx Incorporated (NASDAQ:ACLX) is one of 17 Biotech Stocks With More Than 50% Up.
On February 12, Qize Ding of Rothschild & Co Redburn downgraded Arcellx Incorporated (NASDAQ:ACLX) from Buy to Neutral. In the process, it also lowered the price target from $113 to $82, still yielding a revised upside potential of nearly 20%. Ding’s views are based on his conservative stance on the company’s CAR-T cell therapy class amid growing competition in larger markets in other modalities.
Copyright: wavebreakmediamicro / 123RF Stock Photo
On February 9, Stifel analyst Stephen Willey reaffirmed his Buy rating on Arcellx Incorporated (NASDAQ:ACLX), with a price target of $127. Its forecast points to a potential increase of 85% compared to the current level.
Willey’s rating came after the company presented new data from laboratory studies at the TANDEM meeting. He highlighted that the findings support anito-cel’s potentially leading safety profile, showing lower off-target immune activity and fewer off-target effects than rival CAR-T treatments. The analyst also noted differences with cilta-cel (Carvykti) and ide-cel (Abecma), suggesting that their off-target interactions could be related to serious delayed side effects seen in clinical use. Additionally, Willey believes the data strengthens anito-cel’s positioning as a potentially best-in-class therapy and continues to view the stock as a “core mid-cap holding.”
Arcellx Incorporated (NASDAQ:ACLX) develops advanced immunotherapies for cancer patients and people with other incurable conditions. The company leverages its proprietary D-Domain technology to develop more effective treatments targeting acute myeloid leukemia, multiple myeloma and other malignancies. The current pipeline includes the development of ACLX-001 and ACLX-002, which target BCMA in rrMM and CD123 in AML/MDS.
While we recognize ACLX’s potential as an investment, we believe certain AI stocks offer greater growth potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that’s also benefiting significantly from Trump-era tariffs and the offshoring trend, check out our free report on best short-term AI stock.
READ NEXT: 15 Most Promising Mid-Cap Healthcare Stocks Under $50 and 11 Most Promising Small Cap Industrial Stocks Under $50.
Disclosure: None. This article was originally published in Internal jumpsuit.